Expression of semaphorin 3A (SEMA3A) in breast cancer subtypes
Abstract Breast cancer is a major health concern, and its accurate diagnosis and management depend on identifying its histological type and biological subtype. Semaphorin-3A (SEMA3A) is a membrane protein with diverse roles in cellular processes, including cancer progression and angiogenesis regulat...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-01-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-024-51796-z |
| _version_ | 1827329308630188032 |
|---|---|
| author | Natalia Andryszak Paweł Kurzawa Monika Krzyżaniak Marek Ruchała Michał Nowicki Dariusz Iżycki Rafał Czepczyński |
| author_facet | Natalia Andryszak Paweł Kurzawa Monika Krzyżaniak Marek Ruchała Michał Nowicki Dariusz Iżycki Rafał Czepczyński |
| author_sort | Natalia Andryszak |
| collection | DOAJ |
| description | Abstract Breast cancer is a major health concern, and its accurate diagnosis and management depend on identifying its histological type and biological subtype. Semaphorin-3A (SEMA3A) is a membrane protein with diverse roles in cellular processes, including cancer progression and angiogenesis regulation. However, its role in breast cancer remains poorly understood. This study aimed to evaluate SEMA3A expression in breast cancer and investigate its distribution across breast cancer subtypes: luminal A, luminal B, HER2-positive, and triple-negative breast cancer (TNBC). Immunohistochemical evaluation was performed on 98 breast cancer patients' tumor specimens, and SEMA3A expression was assessed in tumor cells and vessels. The study included the analysis of the Ki67 proliferation index, estrogen receptor (ER) expression, progesterone receptor (PR) expression, and HER2 status in conjunction with SEMA3A expression. Analysis indicated positive expression of SEMA3A in breast cancer cells in 60 out of 98 cases. SEMA3A expression correlated positively with Ki67 levels in tumor cells (p = 0.0005, R Spearman 0.338). Notably, a negative correlation was found between SEMA3A expression and ER and PR levels in tumor cells (p = 0.04, Spearman's R = − 0.21 and p = 0.016, Spearman's R = − 0.25 respectively). HER2 status did not significantly influence SEMA3A expression. The study demonstrated positive SEMA3A expression in tumor vessels across all subtypes in 91 out of 98 cases, suggesting its involvement in endothelial cell function. However, no significant differences in SEMA3A expression were observed between breast cancer subtypes either in vessels or tumor cells. These findings suggest that elevated SEMA3A expression may be associated with worse prognosis in breast cancer, especially in ER- and PR-negative tumors. Further investigations are warranted to fully comprehend the role of SEMA3A in breast cancer biology, which may lead to the identification of novel therapeutic targets and personalized treatment strategies for breast cancer patients. |
| first_indexed | 2024-03-07T15:31:05Z |
| format | Article |
| id | doaj.art-caae68355f9d4e1fbdb5bc71a239e3a6 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-03-07T15:31:05Z |
| publishDate | 2024-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-caae68355f9d4e1fbdb5bc71a239e3a62024-03-05T16:25:15ZengNature PortfolioScientific Reports2045-23222024-01-011411810.1038/s41598-024-51796-zExpression of semaphorin 3A (SEMA3A) in breast cancer subtypesNatalia Andryszak0Paweł Kurzawa1Monika Krzyżaniak2Marek Ruchała3Michał Nowicki4Dariusz Iżycki5Rafał Czepczyński6Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical SciencesDepartment of Oncological Pathology, University Clinical Hospital in Poznan, Poznan University of Medical SciencesDepartment of Oncological Pathology, University Clinical Hospital in Poznan, Poznan University of Medical SciencesDepartment of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical SciencesDepartment of Histology and Embryology, Poznan University of Medical SciencesDepartment of Cancer Immunology, Poznan University of Medical SciencesDepartment of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical SciencesAbstract Breast cancer is a major health concern, and its accurate diagnosis and management depend on identifying its histological type and biological subtype. Semaphorin-3A (SEMA3A) is a membrane protein with diverse roles in cellular processes, including cancer progression and angiogenesis regulation. However, its role in breast cancer remains poorly understood. This study aimed to evaluate SEMA3A expression in breast cancer and investigate its distribution across breast cancer subtypes: luminal A, luminal B, HER2-positive, and triple-negative breast cancer (TNBC). Immunohistochemical evaluation was performed on 98 breast cancer patients' tumor specimens, and SEMA3A expression was assessed in tumor cells and vessels. The study included the analysis of the Ki67 proliferation index, estrogen receptor (ER) expression, progesterone receptor (PR) expression, and HER2 status in conjunction with SEMA3A expression. Analysis indicated positive expression of SEMA3A in breast cancer cells in 60 out of 98 cases. SEMA3A expression correlated positively with Ki67 levels in tumor cells (p = 0.0005, R Spearman 0.338). Notably, a negative correlation was found between SEMA3A expression and ER and PR levels in tumor cells (p = 0.04, Spearman's R = − 0.21 and p = 0.016, Spearman's R = − 0.25 respectively). HER2 status did not significantly influence SEMA3A expression. The study demonstrated positive SEMA3A expression in tumor vessels across all subtypes in 91 out of 98 cases, suggesting its involvement in endothelial cell function. However, no significant differences in SEMA3A expression were observed between breast cancer subtypes either in vessels or tumor cells. These findings suggest that elevated SEMA3A expression may be associated with worse prognosis in breast cancer, especially in ER- and PR-negative tumors. Further investigations are warranted to fully comprehend the role of SEMA3A in breast cancer biology, which may lead to the identification of novel therapeutic targets and personalized treatment strategies for breast cancer patients.https://doi.org/10.1038/s41598-024-51796-z |
| spellingShingle | Natalia Andryszak Paweł Kurzawa Monika Krzyżaniak Marek Ruchała Michał Nowicki Dariusz Iżycki Rafał Czepczyński Expression of semaphorin 3A (SEMA3A) in breast cancer subtypes Scientific Reports |
| title | Expression of semaphorin 3A (SEMA3A) in breast cancer subtypes |
| title_full | Expression of semaphorin 3A (SEMA3A) in breast cancer subtypes |
| title_fullStr | Expression of semaphorin 3A (SEMA3A) in breast cancer subtypes |
| title_full_unstemmed | Expression of semaphorin 3A (SEMA3A) in breast cancer subtypes |
| title_short | Expression of semaphorin 3A (SEMA3A) in breast cancer subtypes |
| title_sort | expression of semaphorin 3a sema3a in breast cancer subtypes |
| url | https://doi.org/10.1038/s41598-024-51796-z |
| work_keys_str_mv | AT nataliaandryszak expressionofsemaphorin3asema3ainbreastcancersubtypes AT pawełkurzawa expressionofsemaphorin3asema3ainbreastcancersubtypes AT monikakrzyzaniak expressionofsemaphorin3asema3ainbreastcancersubtypes AT marekruchała expressionofsemaphorin3asema3ainbreastcancersubtypes AT michałnowicki expressionofsemaphorin3asema3ainbreastcancersubtypes AT dariuszizycki expressionofsemaphorin3asema3ainbreastcancersubtypes AT rafałczepczynski expressionofsemaphorin3asema3ainbreastcancersubtypes |